CN1531925A - 一种制备古拉替莫固体制剂的工艺及其固体制剂 - Google Patents
一种制备古拉替莫固体制剂的工艺及其固体制剂 Download PDFInfo
- Publication number
- CN1531925A CN1531925A CNA031210880A CN03121088A CN1531925A CN 1531925 A CN1531925 A CN 1531925A CN A031210880 A CNA031210880 A CN A031210880A CN 03121088 A CN03121088 A CN 03121088A CN 1531925 A CN1531925 A CN 1531925A
- Authority
- CN
- China
- Prior art keywords
- colatemo
- solid preparation
- microcrystalline cellulose
- solid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 239000007787 solid Substances 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 15
- 239000011734 sodium Substances 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 15
- 239000008107 starch Substances 0.000 claims abstract description 15
- 235000019698 starch Nutrition 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 26
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 26
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000004531 microgranule Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 4
- -1 carboxylmethyl Chemical group 0.000 abstract description 2
- 238000000227 grinding Methods 0.000 abstract 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004137 mechanical activation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229950003909 iguratimod Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003701 mechanical milling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
实施例 | 1 | 2 | 3 |
溶出率(%) | 101.2 | 95.6 | 95.2 |
剂型 | AUC(μg.h/ml) | Cmax(μg/ml) | Tpeak(h) |
原料 | 13.069 | 1.161 | 3.0 |
片剂 | 17.149 | 1.415 | 4.0 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031210880A CN100387231C (zh) | 2003-03-24 | 2003-03-24 | 一种制备古拉替莫固体制剂的工艺及其固体制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031210880A CN100387231C (zh) | 2003-03-24 | 2003-03-24 | 一种制备古拉替莫固体制剂的工艺及其固体制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1531925A true CN1531925A (zh) | 2004-09-29 |
CN100387231C CN100387231C (zh) | 2008-05-14 |
Family
ID=34285566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031210880A Expired - Lifetime CN100387231C (zh) | 2003-03-24 | 2003-03-24 | 一种制备古拉替莫固体制剂的工艺及其固体制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100387231C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931159B (zh) * | 2005-09-16 | 2010-05-12 | 天津药物研究院 | 艾拉莫德微粉化及口服速释制剂 |
CN101095671B (zh) * | 2006-06-26 | 2011-10-19 | 天津药物研究院 | 艾拉莫德口服双层控释制剂 |
CN107582537A (zh) * | 2017-09-26 | 2018-01-16 | 江苏正大清江制药有限公司 | 一种艾拉莫德的药物组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
JP3521145B2 (ja) * | 1993-04-09 | 2004-04-19 | 富山化学工業株式会社 | 免疫調節剤,細胞接着阻害剤および自己免疫疾患の治療・予防剤 |
JP4608087B2 (ja) * | 1999-12-22 | 2011-01-05 | 富山化学工業株式会社 | 固形製剤の製造法 |
-
2003
- 2003-03-24 CN CNB031210880A patent/CN100387231C/zh not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931159B (zh) * | 2005-09-16 | 2010-05-12 | 天津药物研究院 | 艾拉莫德微粉化及口服速释制剂 |
CN101095671B (zh) * | 2006-06-26 | 2011-10-19 | 天津药物研究院 | 艾拉莫德口服双层控释制剂 |
CN107582537A (zh) * | 2017-09-26 | 2018-01-16 | 江苏正大清江制药有限公司 | 一种艾拉莫德的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100387231C (zh) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1309374C (zh) | 改进的快速崩解的多颗粒片剂 | |
CN1805738A (zh) | 持续释放的二甲双胍片剂 | |
CN1084616C (zh) | 扑热息痛和哌双咪酮的膜包衣片剂 | |
CN1931159B (zh) | 艾拉莫德微粉化及口服速释制剂 | |
CN1531925A (zh) | 一种制备古拉替莫固体制剂的工艺及其固体制剂 | |
CN1943586A (zh) | 一种以罗红霉素与盐酸氨溴索为活性成分的口腔崩解片及其制备方法、用途 | |
CN103054820A (zh) | 一种盐酸决奈达隆药物组合物及其制备方法 | |
CN1208345A (zh) | 包含托芬那酸或其医药可接受盐的快速释出片剂及其制法 | |
CN1903208A (zh) | 阿德福韦酯口崩片药物制剂及其制备方法 | |
CN101095671B (zh) | 艾拉莫德口服双层控释制剂 | |
CN1323667C (zh) | 三七分散片及其制备方法 | |
CN1287797C (zh) | 更昔洛韦分散片及其制备方法 | |
CN100341495C (zh) | 格列本脲固体分散体、口服组合物及其制备方法 | |
CN1245163C (zh) | 葛根素分散片组合物及其制备方法 | |
CN1634045A (zh) | 复方法莫替丁咀嚼片制备方法 | |
CN1768751A (zh) | 酚麻美愈分散片的制备方法 | |
CN1733137A (zh) | 颠茄分散片及其制法 | |
CN1692909A (zh) | 多司马酯分散片及其制备办法 | |
CN1684666A (zh) | 制备莫达非尼口服剂型的方法 | |
CN1698792A (zh) | 裸花紫珠分散片及其制备方法 | |
CN1636558A (zh) | 含有布洛芬的药片及其制造方法 | |
CN1049114C (zh) | 一种制备缓释药物制剂的方法 | |
CN1875967A (zh) | 鞣酸苦参碱分散片的制备方法 | |
CN1919184A (zh) | 吗替麦考酚酯分散片及其制备方法 | |
CN1602948A (zh) | 银杏叶分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Patentee after: SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Patentee before: Hainan Simcere Pharmaceutical Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161017 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Patentee after: SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Patentee before: SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Co-patentee after: Hainan Simcere Pharmaceutical Co.,Ltd. Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Co-patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Co-patentee before: SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Co-patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20080514 |
|
CX01 | Expiry of patent term |